Humedix Co., Ltd. (200670.KQ)
KRW 41350.0
(-2.48%)
KRW 41350.0
(-2.48%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 24.82 Billion KRW | 17.71% |
| 2022 | 21.08 Billion KRW | 132.62% |
| 2021 | 9.06 Billion KRW | -39.91% |
| 2020 | 15.08 Billion KRW | 44.76% |
| 2019 | 10.42 Billion KRW | 13.17% |
| 2018 | 9.2 Billion KRW | -22.89% |
| 2017 | 11.94 Billion KRW | 16.21% |
| 2016 | 10.27 Billion KRW | 88303.11% |
| 2015 | 11.62 Million KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 9.26 Billion KRW | 185.39% |
| 2024 Q2 | 11.85 Billion KRW | 28.01% |
| 2023 Q1 | 11.07 Billion KRW | 693.27% |
| 2023 Q4 | 3.24 Billion KRW | -55.01% |
| 2023 FY | 24.82 Billion KRW | 17.71% |
| 2023 Q3 | 7.21 Billion KRW | 119.93% |
| 2023 Q2 | 3.28 Billion KRW | -70.39% |
| 2022 Q1 | 10.35 Billion KRW | 1156.0% |
| 2022 Q4 | -1.86 Billion KRW | -130.09% |
| 2022 FY | 21.08 Billion KRW | 132.62% |
| 2022 Q3 | 6.2 Billion KRW | -2.91% |
| 2022 Q2 | 6.39 Billion KRW | -38.26% |
| 2021 Q3 | 2.39 Billion KRW | -12.56% |
| 2021 Q1 | 3.1 Million KRW | -54.32% |
| 2021 Q2 | 2.73 Billion KRW | 88100.52% |
| 2021 Q4 | 824.39 Million KRW | -65.58% |
| 2021 FY | 9.06 Billion KRW | -39.91% |
| 2020 Q1 | 985.69 Thousand KRW | -67.82% |
| 2020 FY | 15.08 Billion KRW | 44.76% |
| 2020 Q4 | 6.79 Million KRW | 103.37% |
| 2020 Q3 | 3.34 Million KRW | -15.48% |
| 2020 Q2 | 3.95 Million KRW | 301.32% |
| 2019 Q3 | 2.71 Million KRW | 19.92% |
| 2019 Q2 | 2.26 Million KRW | -5.08% |
| 2019 Q1 | 2.38 Million KRW | 2.9% |
| 2019 FY | 10.42 Billion KRW | 13.17% |
| 2019 Q4 | 3.06 Million KRW | 12.92% |
| 2018 Q4 | 2.31 Million KRW | -20.9% |
| 2018 FY | 9.2 Billion KRW | -22.89% |
| 2018 Q1 | 2.03 Million KRW | -11.24% |
| 2018 Q2 | 1.92 Million KRW | -5.19% |
| 2018 Q3 | 2.92 Million KRW | 51.74% |
| 2017 Q2 | 4.03 Million KRW | 78.92% |
| 2017 FY | 11.94 Billion KRW | 16.21% |
| 2017 Q1 | 2.25 Million KRW | 29.9% |
| 2017 Q4 | 2.29 Million KRW | -31.63% |
| 2017 Q3 | 3.35 Million KRW | -16.95% |
| 2016 Q2 | 3.15 Million KRW | 2.32% |
| 2016 Q1 | 3.08 Million KRW | 0.0% |
| 2016 FY | 10.27 Billion KRW | 88303.11% |
| 2016 Q3 | 2.3 Million KRW | -27.07% |
| 2016 Q4 | 1.73 Million KRW | -24.48% |
| 2015 FY | 11.62 Million KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.42 Billion KRW | 227.761% |
| CMG Pharmaceutical Co., Ltd. | 6.45 Billion KRW | -284.498% |
| Celltrion Pharm, Inc. | 21.26 Billion KRW | -16.721% |
| Huons Global Co., Ltd. | 38.38 Billion KRW | 35.335% |
| DongKook Pharmaceutical Co., Ltd. | 47.17 Billion KRW | 47.386% |
| Enzychem Lifesciences Corporation | -9.32 Billion KRW | 366.133% |
| Boditech Med Inc. | 25.94 Billion KRW | 4.339% |
| EuBiologics Co., Ltd. | -13.87 Billion KRW | 278.837% |
| FutureChem Co.,Ltd | -6.7 Billion KRW | 469.964% |
| Huons Co., Ltd. | 50.47 Billion KRW | 50.824% |
| BNC Korea Co., Ltd. | 25.68 Billion KRW | 3.369% |
| AptaBio Therapeutics Inc. | -12.06 Billion KRW | 305.782% |